Abstract Coronavirus disease (COVID‐19) is a highly contagious respiratory infection
caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 …

Introduction This systematic review and meta‐analysis aims to investigate the mutual impact
of COVID‐19 and psoriasis to inform clinical practice and future research. Methods We …

Dear Editor, The recent outbreak of coronavirus disease 19 (COVID-19), caused by the virus
SARS-CoV-2, led to a series of containment and preventive measures to limit its spread …

The new coronavirus pandemic poses question and challenges for dermatologists. One of
question is if psoriasis patients treated with immunomodulating and immunosuppressive …

Background There is concern about susceptibility of psoriatic patients on biologics to
coronavirus disease 2019 (COVID-19) and its clinical course. Purpose The aims of present …

With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is
uncertainty whether biologic agents for psoriasis may place patients at a higher risk for …

The COVID‐19 has been spreading around the world. Concerns about the safety of
administration of immunosuppressive drugs have been raised for treatment of psoriasis …

Coronavirus disease 2019 (COVID-19), a new form of acute infectious respiratory syndrome
first reported in 2019, has rapidly spread worldwide and has been recognized as a …

Background The multimorbid burden and use of systemic immunosuppressants in people
with psoriasis may confer greater risk of adverse outcomes of coronavirus disease 2019 …

Objective To update guidance regarding the management of psoriatic disease during the
COVID-19 pandemic. Study Design The task force (TF) includes 18 physician voting …